Vanderbilt Institute for Clinical and Translational Research (VICTR)

联系PD/PI：Bernard，Gordon R 范德比尔特临床与翻译研究所(VICTR)是一个功能强大、 集成的临床和转换(C&T)研究基础设施，提高了质量和 范德比尔特和长期合作伙伴Meharry进行的科学严谨的研究， 美国历史上最古老的黑人学术健康科学机构。卢旺达问题国际法庭将为 CTSA方案的使命，同时利用卢旺达问题国际法庭的独特资源和专门知识 集中和提升卫生公平在科技研究中的作用，实现这些新目标：1)发挥杠杆作用 卢旺达问题国际法庭强大的合作活力，以增强团队科学方法，整合 研究所有阶段的社区参与原则，并实施设计的计划 支持研究中的健康公平；2)开发和共享多维数据组织 公布研究创新、效率、质量和公平的方法和信息学工具； 3)确保翻译科学员工队伍多样化，并拥有技能、知识和 在卫生公平框架内推进成果转化所需的资源；4) 支持地方研究的效率、质量、代表性和影响，并`提高标准‘ 在研究行为中达到可接受的科学标准；5)支持效率、质量、 通过建立和传播多站点临床试验的代表性和影响 精简方案和促进新的试验设计；以及6)利用独特的体制 能够在医疗保健操作和重新调整用途期间进行务实试验 用于新适应症的现有药物。

Contact PD/PI: Bernard, Gordon R The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub and elevating the role of health equity in C&T research with these new aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies, integrate community engagement principles for all stages of research, and implement programs designed to support health equity in research; 2) Develop and share multi-dimensional data organization methods and informatics tools to promulgate innovation, efficiency, quality, and equity in research; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries within a health equity framework; 4) Support the efficiency, quality, representativeness, and impact of local studies and `raise the bar' for acceptable scientific standards in research conduct; 5) Support the efficiency, quality, representativeness, and impact of multi-site clinical trials by building and disseminating streamlining programs and promoting novel trial designs; and 6) Utilize unique institutional capabilities to enable the conduct of pragmatic trials during healthcare operations and repurpose existing drugs for new indications.